Herpes Labialis Treatment Market

Herpes Labialis Treatment Market: Strong Presence of Key Players in US Underpins North America's Regional Preeminence: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

  • 2018-03-19
  • REP-GB-6461
  • 218 pages
  • PDF PPT EXCEL
Herpes Labialis Treatment Market

An Incisive, In-depth Analysis on the Herpes Labialis Treatment Market

This study offers a comprehensive, 360 degree analysis on the Herpes Labialis Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Herpes Labialis Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

The global market for herpes labialis treatment is poised to expand at a moderate CAGR of 4.6% over 2017-2027. Up from US$ 869.3 Mn achieved in 2017, the global herpes labialis treatment market will possibly reach beyond US$ 1.3 Bn by the end of 2027.

Soaring penetration of generics and frequent transformations in disease treatment will collectively push the market up, whereas innovations in drug type and mode of action will accelerate the demand for herpes labialis treatment in near future. Apart from increasing prevalence of viral infections and rising R&D investments, mergers and acquisitions among the leading companies will also play a crucial role in uplifting the market performance.

Key Players Strongly Support North America’s Dominance

With over 35% value share, North America stood the top market for herpes labialis treatment in 2017. This region is expected to continue its dominance through the forecast period, followed by Western Europe, which recorded over 20% share of the total market value in 2017. APEJ and MEA are also slated for decent market value shares over the assessment period. The North American market is foreseen to take a moderate leap from US$ 310.3 Mn (2017) to US$ 457.1 Mn by the end of forecast period at a CAGR of 3.9%. While the US is expected to maintain dominance, Canada is presumed to witness higher growth during the 10-year period. Increasing efforts and investments in examining clinical efficacy of drugs through research and development, frequent product innovation, and rapid development of cost-effective and advanced treatment options are identified to be the key factors strengthening the growth of North America’s market for herpes labialis treatment.

US-based Companies Lead Market, Extended Product Portfolio Remains Paramount

A majority of US-based leaders in market are concentrating on new product launches through organic and inorganic growth. While strategic collaborations are likely to provide the market with a significant thrust, expansion of existing product portfolio is likely to be the agenda for key players. As FDI policies regulating the pharmaceuticals industry within developing economies are often considered relatively more liberal, established global herpes labialis treatment market players are most likely to amplify their mark within developing regions over the forecast period.

  • Pfizer Inc., one of the leading players in herpes labialis treatment market, is a New York-based company. With a flagship product - Acyclovir sodium injection, which is a pharmaceutical product used as an antiviral agent, this brand sells in two segments viz. essential health and innovative health. Acquisition of a leader in biosimilar and injectable - Hospira Inc. has helped the company to expand its portfolio in herpes injectable.

  • Mylan NV, based in Canonsburg, is a leader in Valacyclovir, Acyclovir, and Famciclovir. While the company already has a diversified product portfolio including a vast range of generics and specialty products, it has recently widened its R&D infrastructure post-acquisition of Meda Pharma. Generic drug approvals seem to be a booster for several opportunities in the herpes infection treatment market. In April 2017, Mylan Pharmaceuticals (subsidiary) received US FDA’s final approval for Acyclovir Ointment USP.

  • Abbott Laboratories is based in Illinois and specializes in Acyclovir Sodium – an injectable antiviral agent. With a broad portfolio serving over 150 countries, the company is currently focusing on expanding its presence in Indian, Chinese, Russian, Colombian, and a few other developing markets. Growing R&D expenditure is foreseen to aid the company in near future. The company divested its branded generics business in developed markets and retained the business in emerging markets in order to capitalize the growing emerging branded generics market.

Future Market Insights’ report on the global herpes labialis treatment market offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analysing data gathered from industry analysts and market participants across key points in the industry’s value chain. A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report

  • A complete backdrop analysis, which includes an assessment of the parent market

  • Important changes in market dynamics

  • Market segmentation up to the second or third level

  • Historical, current, and projected size of the market from the standpoint of both value and volume

  • Reporting and evaluation of recent industry developments

  • Market shares and strategies of key players

  • Emerging niche segments and regional markets

  • An objective assessment of the trajectory of the market

  • Recommendations to companies for strengthening their foothold in the market

  • Global Healthcare Sector Outlook

  • Research Methodology

Market Taxonomy

Dug type

Route of administration

Distribution channel

Region

  • Acyclovir

  • Topical

  • Hospital pharmacies

  • North America

  • Valacyclovir

  • Oral

  • Retail pharmacies

  • Latin America

  • Famciclovir

 

  • Drug stores

  • Western Europe

  • Penciclovir

 

  • Online pharmacies

  • Eastern Europe

  • Docosanol

 

 

  • APEJ

 
 
 
  • Japan
 
 
 
  • MEA

 Future Market Insights utilises a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information. Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information. Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level. On the other hand, the report also analyses various companies’ annual reports, investor presentations, SEC filings, 10k reports, and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints, and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Standard Report Structure

  • Executive Summary

  • Market Definition

  • Macro-economic analysis

  • Parent Market Analysis

  • Market Overview

  • Forecast Factors

  • Segmental Analysis and Forecast

  • Regional Analysis

  • Competition Analysis

Key Questions Answered

  • How the market has performed over the past few years?

  • What have been the challenges for market participants and how did they overcome them?

  • How has the disease and its treatment method evolved over the past years?

  • How the competitors have performed and what have been their growth strategies?

  • What is the market potential expected to look like in near future on a global level?

  • How to sustain and grow market share?

  • What should be the future course of action?

  • Where do I currently stand?

  • Which are the segments, factors, regions offering promising growth potential?

  • What are the trends in the market and am I ready for them?

Herpes Labialis Treatment Market Reports - Table of Contents

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology